DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced or recurrent squamous cell carcinoma of the cervix not curable by surgery or radiotherapy
• Measurable disease
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• SGOT or SGPT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• No active congestive heart failure
• No uncontrolled angina
• No myocardial infarction within the past 6 months
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No concurrent serious infection
• No other malignancy within the past 5 years except nonmelanomatous skin cancer
• No other life threatening illness
• No psychosis, mental disability, or incompetence
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent biologic therapy
• Chemotherapy:
• At least 4 weeks since prior chemotherapy
• No more than 1 prior chemotherapy regimen (except chemotherapy for radiosensitization)
• No prior camptothecin
• No other concurrent chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• At least 4 weeks since prior surgery
• No concurrent surgery
• Other:
• At least 4 weeks since other prior investigational drugs (including analgesics or antiemetics)
• No other concurrent investigational drugs during or within 28 days after final dose of study drug
• No concurrent drugs that induce or inhibit CYP3A enzyme